orserdu
stemline therapeutics b.v. - elacestrant - bryst neoplasms - endokrin terapi - orserdu monotherapy is indicated for the treatment of postmenopausal women, and men, with estrogen receptor (er) positive, her2-negative, locally advanced or metastatic breast cancer with an activating esr1 mutation who have disease progression following at least one line of endocrine therapy including a cdk 4/6 inhibitor.
viread 245 mg
2care4 - tenofovirdisoproksilfumarat - tablett, filmdrasjert - 245 mg
nicotinell 21 mg/24 timer
haleon denmark aps - nikotin - depotplaster - 21 mg/24 timer
nicotinell 7 mg/24 timer
haleon denmark aps - nikotin - depotplaster - 7 mg/24 timer
nicotinell 14 mg/24 timer
haleon denmark aps - nikotin - depotplaster - 14 mg/24 timer
scopoderm 1 mg/72 timer
baxter medical ab - skopolamin - depotplaster - 1 mg/72 timer
voltarol 12.5 mg
glaxosmithkline consumer healthcare a/s (1) - diklofenakkalium - kapsel, myk - 12.5 mg
voltarol 25 mg
glaxosmithkline consumer aps - diklofenakkalium - kapsel, myk - 25 mg
voltarol 25 mg
glaxosmithkline consumer aps - diklofenakkalium - tablett, drasjert - 25 mg
voltarol 12.5 mg
glaxosmithkline consumer aps - diklofenakkalium - tablett, filmdrasjert - 12.5 mg